CMIC Group

Name

CMIC Group

Legal name

CMIC HOLDINGS Co., Ltd.

Website

https://en.cmicgroup.com/

Company type

Public

Founded year

1985

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Research & Development Services

NAICS

Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Post-Acute Care Networks & Care Management Organizations (HLAFAFAN), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Pharmaceutical CRO services
• Contract development manufacturing
• Clinical research services
• Drug development consulting
• Site management organization

Headquarters

HQ city

Hoffman Estates

HQ country

United States

HQ region

North America

Offices46 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Clinical CRO Services: Comprehensive clinical research services from Phase I to Phase IV studies, including regulatory affairs, clinical operations, statistical analysis, pharmacovigilance, data management, and project management
2. Non-Clinical CRO Services: Bioanalysis, GLP analytical testing, safety pharmacology, toxicology, and efficacy studies for pre-clinical drug development
3. CDMO Services: Contract development and manufacturing services including formulation development, investigational product manufacturing, packaging and labeling, release testing, technology transfer, and commercial supply
4. Site Management (SMO) Services: Clinical research coordinator services, clinical site administration, and patient recruitment services supporting site-level clinical trial operations
5. Sales and Marketing Services: Contract sales organization (CSO) services including sales team establishment, sales staff dispatch, post-marketing surveillance, and remote communication support
6. Healthcare Solutions: Patient support programs, call center services, drug adherence programs, healthcare digital platforms, and animal health services
7. Strategic Consulting: Regulatory affairs consulting, product lifecycle management, Japan market entry, CMC consulting, and specialized consulting for oncology, orphan drugs, cell and gene therapy

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

CMIC Group is an integrated pharmaceutical value creator providing end-to-end drug development services including Clinical CRO (Phase I-IV trials, regulatory affairs, pharmacovigilance, data management), Non-Clinical CRO (bioanalysis, toxicology, GLP analytical), CDMO (formulation, manufacturing, packaging, commercial supply), SMO (clinical site coordination), CSO (sales team establishment, post-marketing surveillance), and Strategic Consulting (Japan market entry, regulatory, CMC). The firm also operates harmo digital health platforms and patient support programs for healthcare solutions.

Differentiator

Problem solved

Functional benefit

Brands

• harmo: DX support services for hospitals, health management support services for transportation industry
• OrphanPacific
• CMIC Healthcare Institute
• CMIC CMO
• CMIC Bio

Products and services

• Clinical CRO Solutions Full-service clinical research organization offering clinical development services from Phase I to Phase IV clinical studies, including regulatory affairs, clinical operations, data management, statistical analysis, pharmacovigilance, project management, decentralized clinical trials, and patient recruitment for global pharmaceutical and biotech companies seeking Japan and Asia-Pacific market entry.
• Non-Clinical CRO Solutions Pre-clinical drug development services covering bioanalysis for small molecules, large molecules, oligonucleotides, and biomarkers; GLP-compliant analytical testing; toxicity, safety pharmacology, efficacy, and genotoxicity studies; CMC and GMP analytical services; and non-invasive medical imaging for non-clinical research.
• Contract Development and Manufacturing (CDMO) Solutions Contract development and manufacturing services including formulation/process/analytical development, investigational product manufacturing, packaging and labeling, release and stability testing, technology transfer, and commercial supply, delivered through ISO 14001-certified plants in Japan, Korea, and the United States.
• Site Management Organization (SMO) Solutions Clinical site-level support services including clinical research coordinator (CRC) staffing, clinical site administration, and patient recruitment services supporting hospital and clinic-based clinical trial operations in Japan.
• Sales and Marketing (CSO) Solutions Contract Sales Organization services providing sales team establishment, sales staff (MR) dispatch, post-marketing surveillance, self-inspection support, and remote communication services for pharmaceutical companies marketing products in Japan.
• Strategic and Regulatory Consulting Strategic pharmaceutical consulting services covering Japan market entry, regulatory affairs consulting, CMC consulting, clinical development strategy, product lifecycle management, medical device and IVD regulatory pathways, cell and gene therapy advisory, and national health insurance/drug pricing strategy.
• harmo Healthcare Digital Platforms Personal Health Record (PHR) digital platform comprising harmo Vaccination Care for vaccination tracking and harmo Prescription Record for prescription drug management, supporting hospitals and patients with health data integration and DX support.
• Patient and Healthcare Support Solutions Patient and healthcare support services including call center operations, drug adherence support programs, and animal health services supporting pharmaceutical commercialization and patient outcomes.

Named customers4 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core, minor and moderate.

• Dai Nippon Printing Co., Ltd.coreStrategic or Co-development Partner · 1 April 2023Strategic business alliance entered in April 2023 for CMIC CMO Group. In June 2023, Dai Nippon Printing became an equity-method affiliate from a consolidated subsidiary, representing a significant strategic partnership in the CDMO business.
• Stockport Advisors Co. Ltd.minorStrategic or Co-development Partner · 1 January 2017Founded by Shunji Katayama in 2017 as a strategic and financial advisory firm. Stockport Advisors has advised government-affiliated financial institutions, multinational corporations, and healthcare companies on strategic and financial matters.
• CMIC Shiftzero K.K.moderateStrategic or Co-development Partner · 1 January 2016Joint venture between CMIC Holdings and Shiftzero K.K. established for specialized consulting and project management services. Teruyoshi Okuda served as president and representative director from 2016 to 2023. The partnership provided strategic pharmaceutical development planning and consulting services.
• CMIC-MPSS Co. Ltd.moderateStrategic or Co-development Partner · 1 January 2008Joint venture company focused on Contract Sales Organization (CSO) business within CMIC Group. Established in 2008, Takashi Sano served as President of CMIC-MPSS Co. Ltd. from 2008. The joint venture combines CMIC's pharmaceutical services with partner capabilities for sales team establishment and dispatch services.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Syneos Health: Syneos Health combines clinical CRO and contract sales organization (CSO) services in the same integrated model CMIC operates (CRO + CSO + SMO); the structural similarity makes it the most direct strategic parallel for evaluating CMIC's PVC value proposition.
• ICON plc: ICON plc is a global clinical CRO with similar Phase I–IV capabilities to CMIC and competes for multi-region biotech and pharma sponsors, particularly on Japan-included trials where CMIC's domestic expertise is the differentiator.
• IQVIA: IQVIA is the world's largest CRO and competes directly with CMIC on Phase I–IV clinical research, bioanalytical services, and Asia-Pacific trial execution; CMIC's Japan/Korea leadership is the most direct competitive overlap given IQVIA's stated APAC ambitions.
• EPS Holdings: EPS Holdings is a Japan-based CRO and SMO peer that competes head-to-head with CMIC in Japanese clinical trial monitoring, site management, and bioanalytical services; it is the closest pure-play domestic parallel to CMIC's clinical CRO/SMO franchise.
• Medpace Holdings: Medpace is a mid-to-large global clinical CRO competing for biotech and mid-size pharma trials that also require APAC reach; its operating model and Phase I–IV focus make it a direct comparator for clinical execution quality and cost efficiency.
• Wuxi AppTec: Wuxi AppTec operates an integrated CRO + CDMO + SMO platform across Asia (especially China) that parallels CMIC's integrated PVC model; it is the most relevant large-scale APAC integrated peer for cross-region trial and manufacturing outsourcing.
• Charles River Laboratories: Charles River Laboratories provides non-clinical CRO services (safety pharmacology, toxicology, bioanalysis) that directly overlap with CMIC's non-clinical CRO and bioanalysis offerings, and it is building CDMO capabilities adjacent to CMIC CMO.

Broad incumbents

• Parexel International: Parexel is a large established global CRO with Phase I–IV, biostatistics, and regulatory consulting similar in scope to CMIC's clinical CRO and Strategic Consulting unit; it is a relevant incumbent for global sponsor RFPs where CMIC participates as a regional partner.
• Laboratory Corporation of America (LabCorp / Fortrea): LabCorp's former CRO segment (now Fortrea) provides clinical development services that overlap with CMIC's clinical CRO, while LabCorp retains central laboratory and bioanalytical services comparable to CMIC's bioanalysis franchise.

Others

• SGS SA: SGS is acquiring CMIC, INC. (the US bioanalytical lab) to expand its own bioanalytical network; it is a buyer/integrator in CMIC's lab-services value chain rather than a clinical CRO competitor, but the deal makes SGS a direct operator in the same GLP bioanalytical market CMIC served.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CMIC Group